Retiro De Equipo (Recall) de SERODIA HIV;SERODIA HIV1/2

Según L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en France que fue producido por BAYER DIAGNOSTICS.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • Fecha
    1999-11-10
  • País del evento
  • Fuente del evento
    ANSM
  • URL de la fuente del evento
  • Notas / Alertas
    French data is current through early September 2018. All of the data comes from L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and France.
  • Notas adicionales en la data
  • Acción
    As part of its vigilance competence for the products for which it ensures safety, the Agency has reassessed the sensitivity of all HIV-1 antibody test reagents in accordance with protocol approved by the Advisory Committee for the Registration of Reagents. In view of the results of this re-evaluation and following the opinion of the Advisory Committee on the Registration of Reagents (CCER), the French Agency for the Safety of Health Products decided to withdraw from the market of six reagents on 16 June 1999 (message from June 17, 1999). In addition to these decisions, the Agency decided on 9 November 1999 to proceed with the removal of the SERODIA HIV and SERODIA HIV1 / 2 reagents from BAYER DIAGNOSTICS, given the impossibility of improving the performance of these reagents, including sensitivity was close to the acceptance criteria adopted by the CCER.

Device

  • Modelo / Serial
  • Descripción del producto
    in-vitro_medical_device
  • Manufacturer

Manufacturer

  • Empresa matriz del fabricante (2017)
  • Source
    LAANSM